Clinical and neuroimaging correlates of antiphospholipid antibodies in multiple sclerosis: a preliminary study

被引:46
作者
Bidot, Carlos J. [2 ]
Horstman, Lawrence L. [2 ]
Jy, Wenche [2 ]
Jimenez, Joaquin J. [2 ]
Bidot, Carlos, Jr. [2 ]
Ahn, Yeon S. [2 ]
Alexander, J. Steven [3 ,4 ]
Gonzalez-Toledo, Eduardo [1 ,5 ]
Kelley, Roger E. [1 ]
Minagar, Alireza [1 ]
机构
[1] Louisiana State Univ, Dept Neurol, Hlth Sci Ctr, Shreveport, LA 71105 USA
[2] Univ Miami, Dept Med, Miller Sch Med, Wallace H Coulter Platelet Lab, Miami, FL USA
[3] Louisiana State Univ, Dept Mol, Hlth Sci Ctr, Shreveport, LA 71105 USA
[4] Louisiana State Univ, Dept Cellular Physiol, Hlth Sci Ctr, Shreveport, LA 71105 USA
[5] Louisiana State Univ, Dept Radiol, Hlth Sci Ctr, Shreveport, LA 71105 USA
关键词
D O I
10.1186/1471-2377-7-36
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: The presence of antiphospholipid antibodies (APLA) in multiple sclerosis (MS) patients has been reported frequently but no clear relationship between APLA and the clinical and neuroimaging features of MS have heretofore been shown. We assessed the clinical and neuroimaging features of MS patients with plasma APLA. Methods: A consecutive cohort of 24 subjects with relapsing-remitting (RR) MS were studied of whom 7 were in remission (Rem) and 17 in exacerbation (Exc). All subjects were examined and underwent MRI of brain. Patients' plasma was tested by standard ELISA for the presence of both IgM and IgG antibodies using a panel of 6 targets: cardiolipin (CL), beta 2 glycoprotein I (beta 2GPI), Factor VII/VIIa (FVIIa), phosphatidylcholine (PC), phosphatidylserine (PS) and phosphatidylethanolamine (PE). Results: In exacerbation up to 80% of MS subjects had elevated titers of IgM antibodies directed against the above antigens. However, in remission, less than half of MS patients had elevated titers of IgM antibodies against one or more of the above antigens. This difference was significant, p < 0.01, for all 6 target antigens. Interestingly, none of the MS patients had elevated plasma titers of IgG against any of the target antigens tested. Correlation analysis between MRI enhancing lesions and plasma levels of APLA revealed high correlation for aPC, aPS and aFVIIa (p <= 0.0065), a trend for aPE and aCL (p = 0.056), and no correlation for a beta 2GP1. The strongest correlation was for aFVIIa, p = 0.0002. Conclusion: The findings of this preliminary study show that increased APLA IgM is associated with exacerbations of MS. Currently, the significance of this association in pathogenesis of MS remains unknown. However, systematic longitudinal studies to measure APLA in larger cohorts of patients with relapsing-remitting MS, particularly before and after treatment with immunomodulatory agents, are needed to confirm these preliminary findings.
引用
收藏
页数:7
相关论文
共 43 条
[1]
Antiphospholipid antibodies and platelet activation as risk factors for thrombosis in thrombocythaemia [J].
Bidot, CJ ;
Jy, W ;
Horstman, LL ;
Ahn, ER ;
Bidot, L ;
Fontana, V ;
Ahn, YS .
HEMATOLOGY, 2005, 10 (06) :451-456
[2]
Antiphospholipid antibodies in immune thrombocytopenic purpura tend to emerge in exacerbation and decline in remission [J].
Bidot, CJ ;
Jy, W ;
Horstman, LL ;
Ahn, ER ;
Jimenez, JJ ;
Yaniz, M ;
Lander, G ;
Ahn, YS .
BRITISH JOURNAL OF HAEMATOLOGY, 2005, 128 (03) :366-372
[3]
Factor VII/VIIa: a new antigen in the anti-phospholipid antibody syndrome [J].
Bidot, CJ ;
Jy, W ;
Horstman, LL ;
Huisheng, H ;
Jimenez, JJ ;
Yaniz, M ;
Ahn, YS .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (04) :618-626
[4]
BREY RL, 2002, ANTIPHOSPHOLIPID SYN, V2, P155
[5]
CONLEY CL, 1952, J CLIN INVEST, V31, P621
[6]
CONLEY CL, 1948, B JOHNS HOPKINS HOSP, V83, P288
[7]
Constans J, 1998, EUR J CLIN INVEST, V28, P115, DOI 10.1046/j.1365-2362.1998.00254.x
[8]
Multiple sclerosis and antiphospholipid antibodies: study of 62 patients. [J].
Cordoliani, MA ;
Michon-Pasturel, U ;
Rerat, K ;
Arvieux, J ;
Masy, E ;
Hachulla, E ;
Vermersch, P .
REVUE DE MEDECINE INTERNE, 1998, 19 (09) :635-639
[9]
Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature [J].
Cuadrado, MJ ;
Khamashta, MA ;
Ballesteros, A ;
Godfrey, T ;
Simon, MJ ;
Hughes, GRV .
MEDICINE, 2000, 79 (01) :57-68
[10]
DELPAPA N, 1992, CLIN EXP RHEUMATOL, V10, P37